Burlingame, United States
Genesis Molecular AI, founded in 2019 and headquartered in the United States, is advancing the intersection of AI and Biotechnology to expedite new medicine discovery. The company’s proprietary platform, GEMS (Genesis Exploration of Molecular Space), leverages leading-edge generative and predictive AI models to enhance small molecule drug discovery, optimizing the entire process from hit identification to lead optimization and candidate selection.
With facilities in Burlingame, CA, and San Diego, plus offices in New York, Genesis employs the breakthrough generative diffusion model Pearl for structure prediction, making significant strides into traditionally undruggable targets. The strategic AI platform collaborations with companies such as Gilead (starting in 2024) and Incyte (beginning in 2025) further bolster its robust internal pipeline.
The company has secured over $300M in funding from prominent investors like Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (from NVIDIA), BlackRock, and Menlo Ventures. Their latest capital injection was a late-stage VC investment on 01 November 2024 by nVentures.
